In this video interview with Pharmacy Times®, Namrata Shah, MD, infectious disease physician at Whitman-Walker Health and Principal Investigator for the Institute for Health Research & Policy at Whitman-Walker, details the development and recent FDA approval of lenacapavir (Yeztugo; Gilead Sciences) as a twice-yearly subcutaneous pre-exposure prophylaxis (PrEP) option, emphasizing its distinct mechanism of action and long-acting profile.
Originally approved for treatment-experienced individuals with HIV, lenacapavir’s role has expanded due to compelling data from the PURPOSE 1 and 2 trials, which demonstrated up to 100% efficacy in diverse high-risk populations, Shah explains. Shah highlights its potential to improve adherence, reduce stigma, and offer greater autonomy by meeting patients where they are—especially those unable to consistently take daily oral medication.
